Share Price and Basic Stock Data
Last Updated: November 18, 2025, 6:41 pm
| PEG Ratio | 315.10 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Aashka Hospitals Ltd operates in the Hospitals & Medical Services industry, with its stock currently priced at ₹90.00 and a market capitalization of ₹211 Cr. The company has experienced fluctuating revenue trends over the years. For instance, sales rose from ₹27.67 Cr in March 2019 to ₹40.69 Cr in March 2021, before declining to ₹18.94 Cr in March 2023. The trailing twelve-month revenue stood at ₹20.72 Cr. Quarterly sales also showed variability, with a peak of ₹28.42 Cr in September 2021, followed by a significant drop to ₹7.41 Cr in March 2023. The most recent quarter reported sales of ₹10.80 Cr in September 2023, indicating a potential recovery. However, the overall sales trajectory reflects challenges in maintaining consistent revenue growth, which is critical in the competitive healthcare sector. The company’s ability to stabilize and grow its revenues will be essential for its long-term viability.
Profitability and Efficiency Metrics
Aashka Hospitals Ltd’s profitability has been inconsistent, with operating profit margins (OPM) fluctuating significantly. The OPM stood at 21.80% in March 2021 but turned negative at -6.54% in March 2022 and further dropped to -6.75% in March 2023. By March 2024, the OPM rebounded to 30.07%, indicating improved operational efficiency. However, the net profit margin was only 14.42% in March 2024, compared to 5.95% in March 2021. The company recorded a net profit of ₹1.93 Cr in March 2024, a notable recovery from the loss of ₹2.57 Cr in March 2023. The interest coverage ratio (ICR) also demonstrated a healthy figure of 4.41x in March 2024, suggesting that the company can comfortably meet its interest obligations. Nevertheless, the return on equity (ROE) at 2.39% remains low, indicating that shareholder returns are not maximized, which could deter potential investors.
Balance Sheet Strength and Financial Ratios
Aashka Hospitals Ltd’s balance sheet reflects a cautious financial strategy, with no reported borrowings, which indicates a low debt burden. The company’s current ratio improved to 1.29x in March 2024, suggesting better short-term liquidity management compared to the previous year’s 0.64x. The price-to-book value (P/BV) ratio stood at 2.40x, indicating that the stock may be overvalued relative to its book value, which was reported at ₹42.60 per share in March 2024. The enterprise value (EV) of ₹248.61 Cr in March 2024 suggests that the market values the company significantly higher than its net operating revenues, which stands at ₹9.69 per share. Furthermore, the cash conversion cycle was recorded at 4.23 days, reflecting efficient management of working capital. However, the return on capital employed (ROCE) at 4.07% indicates that the company is still struggling to generate sufficient returns on its investments, which is a critical area for improvement.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Aashka Hospitals Ltd reveals a significant promoter holding of 61.34%, which suggests a strong commitment from the company’s founders. The public shareholding accounts for 38.68%, with a declining trend in the number of shareholders, which fell from 2,771 in September 2021 to 1,172 in September 2025. This reduction may indicate waning investor interest, potentially due to inconsistent financial performance. However, the stability in promoter shareholding suggests that the management is confident about the company’s future prospects. The lack of participation from foreign institutional investors (FIIs) and domestic institutional investors (DIIs) could reflect a cautious stance from institutional investors, which may impact liquidity and market perception. Maintaining investor confidence will be critical for Aashka Hospitals as it seeks to navigate through its operational challenges and improve its market standing.
Outlook, Risks, and Final Insight
The outlook for Aashka Hospitals Ltd hinges on its ability to stabilize revenue and improve profitability metrics. The recent recovery in operating margins and net profit suggests potential positive momentum. However, the company faces several risks, including fluctuating revenues, low ROE, and declining shareholder numbers, which could affect investor sentiment and market confidence. Additionally, the healthcare sector is highly competitive, and any operational inefficiencies or regulatory changes could pose significant challenges. Strengths include a low debt position and a committed promoter base, which can provide stability during turbulent times. If Aashka Hospitals can effectively leverage its operational improvements and maintain a strong focus on cost management, it may enhance its financial performance. Conversely, failure to address its profitability issues could lead to further declines in investor confidence and share price volatility.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of Aashka Hospitals Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| NG Industries Ltd | 46.4 Cr. | 139 | 195/125 | 9.48 | 117 | 2.53 % | 23.6 % | 20.7 % | 10.0 |
| Global Longlife Hospital and Research Ltd | 21.2 Cr. | 20.2 | 35.5/18.3 | 24.3 | 0.00 % | 13.7 % | 17.7 % | 10.0 | |
| Gian Lifecare Ltd | 12.0 Cr. | 11.6 | 21.4/11.6 | 133 | 19.1 | 0.00 % | 3.00 % | 0.81 % | 10.0 |
| Fortis Malar Hospitals Ltd | 121 Cr. | 64.3 | 98.7/53.1 | 26.6 | 18.3 | 0.00 % | 0.83 % | 0.56 % | 10.0 |
| Family Care Hospitals Ltd | 21.5 Cr. | 3.98 | 7.60/3.40 | 1.51 | 0.00 % | 79.2 % | 85.5 % | 10.0 | |
| Industry Average | 27,996.36 Cr | 842.13 | 101.54 | 102.21 | 0.27% | 15.48% | 14.81% | 9.04 |
Quarterly Result
| Metric | Mar 2021 | Sep 2021 | Mar 2022 | Sep 2022 | Mar 2023 | Sep 2023 | Mar 2024 | Sep 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Sales | 24.82 | 28.42 | 11.32 | 11.54 | 7.41 | 10.80 | 12.07 | 12.36 | 10.28 |
| Expenses | 19.41 | 19.41 | 12.06 | 10.80 | 7.91 | 9.97 | 8.44 | 7.89 | 10.49 |
| Operating Profit | 5.41 | 9.01 | -0.74 | 0.74 | -0.50 | 0.83 | 3.63 | 4.47 | -0.21 |
| OPM % | 21.80% | 31.70% | -6.54% | 6.41% | -6.75% | 7.69% | 30.07% | 36.17% | -2.04% |
| Other Income | 0.04 | 0.04 | 0.09 | 0.06 | 3.06 | 2.61 | 1.61 | 0.07 | 4.20 |
| Interest | 1.43 | 1.43 | 1.23 | -0.17 | 3.17 | 1.46 | 1.45 | 1.02 | 0.70 |
| Depreciation | 1.45 | 1.45 | 1.44 | 1.44 | 1.49 | 1.47 | 1.45 | 1.58 | 1.37 |
| Profit before tax | 2.57 | 6.17 | -3.32 | -0.47 | -2.10 | 0.51 | 2.34 | 1.94 | 1.92 |
| Tax % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 17.65% | 17.09% | 16.49% | 14.58% |
| Net Profit | 2.57 | 6.17 | -3.33 | -0.47 | -2.10 | 0.42 | 1.93 | 1.62 | 1.65 |
| EPS in Rs | 1.43 | 2.64 | -1.42 | -0.20 | -0.90 | 0.18 | 0.82 | 0.69 | 0.71 |
Last Updated: May 31, 2025, 7:13 am
Below is a detailed analysis of the quarterly data for Aashka Hospitals Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:
- For Sales, as of Mar 2025, the value is 10.28 Cr.. The value appears to be declining and may need further review. It has decreased from 12.36 Cr. (Sep 2024) to 10.28 Cr., marking a decrease of 2.08 Cr..
- For Expenses, as of Mar 2025, the value is 10.49 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 7.89 Cr. (Sep 2024) to 10.49 Cr., marking an increase of 2.60 Cr..
- For Operating Profit, as of Mar 2025, the value is -0.21 Cr.. The value appears to be declining and may need further review. It has decreased from 4.47 Cr. (Sep 2024) to -0.21 Cr., marking a decrease of 4.68 Cr..
- For OPM %, as of Mar 2025, the value is -2.04%. The value appears to be declining and may need further review. It has decreased from 36.17% (Sep 2024) to -2.04%, marking a decrease of 38.21%.
- For Other Income, as of Mar 2025, the value is 4.20 Cr.. The value appears strong and on an upward trend. It has increased from 0.07 Cr. (Sep 2024) to 4.20 Cr., marking an increase of 4.13 Cr..
- For Interest, as of Mar 2025, the value is 0.70 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 1.02 Cr. (Sep 2024) to 0.70 Cr., marking a decrease of 0.32 Cr..
- For Depreciation, as of Mar 2025, the value is 1.37 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 1.58 Cr. (Sep 2024) to 1.37 Cr., marking a decrease of 0.21 Cr..
- For Profit before tax, as of Mar 2025, the value is 1.92 Cr.. The value appears to be declining and may need further review. It has decreased from 1.94 Cr. (Sep 2024) to 1.92 Cr., marking a decrease of 0.02 Cr..
- For Tax %, as of Mar 2025, the value is 14.58%. The value appears to be improving (decreasing) as expected. It has decreased from 16.49% (Sep 2024) to 14.58%, marking a decrease of 1.91%.
- For Net Profit, as of Mar 2025, the value is 1.65 Cr.. The value appears strong and on an upward trend. It has increased from 1.62 Cr. (Sep 2024) to 1.65 Cr., marking an increase of 0.03 Cr..
- For EPS in Rs, as of Mar 2025, the value is 0.71. The value appears strong and on an upward trend. It has increased from 0.69 (Sep 2024) to 0.71, marking an increase of 0.02.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: November 15, 2025, 4:06 am
| Metric | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|
| Sales | 27.67 | 27.23 | 40.69 | 39.73 | 18.94 | 22.87 | 22.65 | 20.72 |
| Expenses | 18.08 | 18.41 | 30.72 | 31.16 | 18.59 | 18.41 | 18.37 | 18.82 |
| Operating Profit | 9.59 | 8.82 | 9.97 | 8.57 | 0.35 | 4.46 | 4.28 | 1.90 |
| OPM % | 34.66% | 32.39% | 24.50% | 21.57% | 1.85% | 19.50% | 18.90% | 9.17% |
| Other Income | 0.06 | 0.02 | 0.00 | 0.13 | 3.10 | 4.21 | 4.26 | 5.10 |
| Interest | 5.75 | 4.90 | 3.25 | 2.96 | 3.09 | 2.91 | 1.72 | 1.33 |
| Depreciation | 2.54 | 2.56 | 2.61 | 2.90 | 2.93 | 2.92 | 2.95 | 2.83 |
| Profit before tax | 1.36 | 1.38 | 4.11 | 2.84 | -2.57 | 2.84 | 3.87 | 2.84 |
| Tax % | 0.00% | 0.00% | 0.00% | 16.55% | 0.00% | 17.25% | 15.50% | |
| Net Profit | 1.36 | 1.38 | 4.11 | 2.37 | -2.57 | 2.36 | 3.27 | 2.43 |
| EPS in Rs | 0.76 | 0.77 | 2.28 | 1.01 | -1.10 | 1.01 | 1.40 | 1.04 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
YoY Net Profit Growth
| Year | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 1.47% | 197.83% | -42.34% | -208.44% | 191.83% | 38.56% |
| Change in YoY Net Profit Growth (%) | 0.00% | 196.36% | -240.16% | -166.10% | 400.27% | -153.27% |
Aashka Hospitals Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 6 years from 2019-2020 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | -4% |
| 3 Years: | -17% |
| TTM: | -1% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 11% |
| 3 Years: | 0% |
| TTM: | -1% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 25% |
| 1 Year: | -27% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 2% |
| 3 Years: | 1% |
| Last Year: | 2% |
Last Updated: September 5, 2025, 2:01 pm
No data available for the Balance Sheet data table.
Cash Flow
| Month | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|
Financial Efficiency Indicators
| Month | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|
| Debtor Days | 45.64 | 90.48 | 65.66 | 71.84 | 132.20 | 76.93 | 76.06 |
| Inventory Days | 51.35 | 66.55 | 30.28 | 34.97 | 56.59 | 48.75 | 58.63 |
| Days Payable | 296.91 | 247.49 | 241.09 | 101.11 | 365.00 | 263.54 | 130.46 |
| Cash Conversion Cycle | -199.92 | -90.46 | -145.15 | 5.71 | -176.21 | -137.86 | 4.23 |
| Working Capital Days | -93.26 | 19.57 | -38.48 | -34.27 | -126.42 | -123.21 | 3.38 |
| ROCE % | 12.14% | 13.12% | 6.38% | 0.42% | 4.80% | 4.07% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 24 | Mar 23 | Mar 22 | Mar 21 | Mar 20 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 1.40 | 1.01 | -1.10 | 1.12 | 2.29 |
| Diluted EPS (Rs.) | 1.40 | 1.01 | -1.10 | 1.12 | 2.29 |
| Cash EPS (Rs.) | 2.66 | 2.26 | 0.15 | 2.25 | 3.73 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 42.60 | 41.20 | 40.19 | 41.32 | 16.25 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 42.60 | 41.20 | 40.19 | 41.32 | 16.25 |
| Revenue From Operations / Share (Rs.) | 9.69 | 9.79 | 8.11 | 17.00 | 22.60 |
| PBDIT / Share (Rs.) | 3.26 | 3.71 | 1.44 | 3.59 | 5.51 |
| PBIT / Share (Rs.) | 2.00 | 2.46 | 0.18 | 2.35 | 4.06 |
| PBT / Share (Rs.) | 1.66 | 1.22 | -1.10 | 1.21 | 2.29 |
| Net Profit / Share (Rs.) | 1.40 | 1.01 | -1.10 | 1.01 | 2.29 |
| PBDIT Margin (%) | 33.62 | 37.92 | 17.75 | 21.12 | 24.36 |
| PBIT Margin (%) | 20.61 | 25.17 | 2.27 | 13.82 | 17.96 |
| PBT Margin (%) | 17.08 | 12.44 | -13.56 | 7.14 | 10.11 |
| Net Profit Margin (%) | 14.42 | 10.30 | -13.56 | 5.95 | 10.11 |
| Return on Networth / Equity (%) | 3.28 | 2.44 | -2.73 | 2.44 | 14.06 |
| Return on Capital Employeed (%) | 4.39 | 5.47 | 0.38 | 4.81 | 14.60 |
| Return On Assets (%) | 2.81 | 1.94 | -2.00 | 1.83 | 6.32 |
| Long Term Debt / Equity (X) | 0.06 | 0.08 | 0.16 | 0.17 | 0.68 |
| Total Debt / Equity (X) | 0.12 | 0.21 | 0.31 | 0.29 | 0.74 |
| Asset Turnover Ratio (%) | 0.19 | 0.18 | 0.14 | 0.40 | 0.65 |
| Current Ratio (X) | 1.29 | 0.64 | 0.79 | 0.82 | 1.01 |
| Quick Ratio (X) | 1.25 | 0.62 | 0.77 | 0.78 | 0.97 |
| Inventory Turnover Ratio (X) | 58.72 | 0.00 | 0.00 | 10.54 | 10.90 |
| Interest Coverage Ratio (X) | 4.41 | 2.98 | 1.12 | 3.16 | 3.10 |
| Interest Coverage Ratio (Post Tax) (X) | 2.36 | 1.81 | 0.14 | 1.89 | 2.29 |
| Enterprise Value (Cr.) | 248.61 | 199.58 | 124.69 | 144.22 | 0.00 |
| EV / Net Operating Revenue (X) | 10.98 | 8.73 | 6.58 | 3.63 | 0.00 |
| EV / EBITDA (X) | 32.65 | 23.00 | 37.06 | 17.18 | 0.00 |
| MarketCap / Net Operating Revenue (X) | 10.54 | 7.92 | 5.20 | 2.95 | 0.00 |
| Price / BV (X) | 2.40 | 1.88 | 1.05 | 1.21 | 0.00 |
| Price / Net Operating Revenue (X) | 10.54 | 7.92 | 5.20 | 2.95 | 0.00 |
| EarningsYield | 0.01 | 0.01 | -0.02 | 0.02 | 0.00 |
After reviewing the key financial ratios for Aashka Hospitals Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 24, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 23) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 24, the value is 1.40. This value is below the healthy minimum of 5. It has increased from 1.01 (Mar 23) to 1.40, marking an increase of 0.39.
- For Diluted EPS (Rs.), as of Mar 24, the value is 1.40. This value is below the healthy minimum of 5. It has increased from 1.01 (Mar 23) to 1.40, marking an increase of 0.39.
- For Cash EPS (Rs.), as of Mar 24, the value is 2.66. This value is below the healthy minimum of 3. It has increased from 2.26 (Mar 23) to 2.66, marking an increase of 0.40.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 24, the value is 42.60. It has increased from 41.20 (Mar 23) to 42.60, marking an increase of 1.40.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 24, the value is 42.60. It has increased from 41.20 (Mar 23) to 42.60, marking an increase of 1.40.
- For Revenue From Operations / Share (Rs.), as of Mar 24, the value is 9.69. It has decreased from 9.79 (Mar 23) to 9.69, marking a decrease of 0.10.
- For PBDIT / Share (Rs.), as of Mar 24, the value is 3.26. This value is within the healthy range. It has decreased from 3.71 (Mar 23) to 3.26, marking a decrease of 0.45.
- For PBIT / Share (Rs.), as of Mar 24, the value is 2.00. This value is within the healthy range. It has decreased from 2.46 (Mar 23) to 2.00, marking a decrease of 0.46.
- For PBT / Share (Rs.), as of Mar 24, the value is 1.66. This value is within the healthy range. It has increased from 1.22 (Mar 23) to 1.66, marking an increase of 0.44.
- For Net Profit / Share (Rs.), as of Mar 24, the value is 1.40. This value is below the healthy minimum of 2. It has increased from 1.01 (Mar 23) to 1.40, marking an increase of 0.39.
- For PBDIT Margin (%), as of Mar 24, the value is 33.62. This value is within the healthy range. It has decreased from 37.92 (Mar 23) to 33.62, marking a decrease of 4.30.
- For PBIT Margin (%), as of Mar 24, the value is 20.61. This value exceeds the healthy maximum of 20. It has decreased from 25.17 (Mar 23) to 20.61, marking a decrease of 4.56.
- For PBT Margin (%), as of Mar 24, the value is 17.08. This value is within the healthy range. It has increased from 12.44 (Mar 23) to 17.08, marking an increase of 4.64.
- For Net Profit Margin (%), as of Mar 24, the value is 14.42. This value exceeds the healthy maximum of 10. It has increased from 10.30 (Mar 23) to 14.42, marking an increase of 4.12.
- For Return on Networth / Equity (%), as of Mar 24, the value is 3.28. This value is below the healthy minimum of 15. It has increased from 2.44 (Mar 23) to 3.28, marking an increase of 0.84.
- For Return on Capital Employeed (%), as of Mar 24, the value is 4.39. This value is below the healthy minimum of 10. It has decreased from 5.47 (Mar 23) to 4.39, marking a decrease of 1.08.
- For Return On Assets (%), as of Mar 24, the value is 2.81. This value is below the healthy minimum of 5. It has increased from 1.94 (Mar 23) to 2.81, marking an increase of 0.87.
- For Long Term Debt / Equity (X), as of Mar 24, the value is 0.06. This value is below the healthy minimum of 0.2. It has decreased from 0.08 (Mar 23) to 0.06, marking a decrease of 0.02.
- For Total Debt / Equity (X), as of Mar 24, the value is 0.12. This value is within the healthy range. It has decreased from 0.21 (Mar 23) to 0.12, marking a decrease of 0.09.
- For Asset Turnover Ratio (%), as of Mar 24, the value is 0.19. It has increased from 0.18 (Mar 23) to 0.19, marking an increase of 0.01.
- For Current Ratio (X), as of Mar 24, the value is 1.29. This value is below the healthy minimum of 1.5. It has increased from 0.64 (Mar 23) to 1.29, marking an increase of 0.65.
- For Quick Ratio (X), as of Mar 24, the value is 1.25. This value is within the healthy range. It has increased from 0.62 (Mar 23) to 1.25, marking an increase of 0.63.
- For Inventory Turnover Ratio (X), as of Mar 24, the value is 58.72. This value exceeds the healthy maximum of 8. It has increased from 0.00 (Mar 23) to 58.72, marking an increase of 58.72.
- For Interest Coverage Ratio (X), as of Mar 24, the value is 4.41. This value is within the healthy range. It has increased from 2.98 (Mar 23) to 4.41, marking an increase of 1.43.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 24, the value is 2.36. This value is below the healthy minimum of 3. It has increased from 1.81 (Mar 23) to 2.36, marking an increase of 0.55.
- For Enterprise Value (Cr.), as of Mar 24, the value is 248.61. It has increased from 199.58 (Mar 23) to 248.61, marking an increase of 49.03.
- For EV / Net Operating Revenue (X), as of Mar 24, the value is 10.98. This value exceeds the healthy maximum of 3. It has increased from 8.73 (Mar 23) to 10.98, marking an increase of 2.25.
- For EV / EBITDA (X), as of Mar 24, the value is 32.65. This value exceeds the healthy maximum of 15. It has increased from 23.00 (Mar 23) to 32.65, marking an increase of 9.65.
- For MarketCap / Net Operating Revenue (X), as of Mar 24, the value is 10.54. This value exceeds the healthy maximum of 3. It has increased from 7.92 (Mar 23) to 10.54, marking an increase of 2.62.
- For Price / BV (X), as of Mar 24, the value is 2.40. This value is within the healthy range. It has increased from 1.88 (Mar 23) to 2.40, marking an increase of 0.52.
- For Price / Net Operating Revenue (X), as of Mar 24, the value is 10.54. This value exceeds the healthy maximum of 3. It has increased from 7.92 (Mar 23) to 10.54, marking an increase of 2.62.
- For EarningsYield, as of Mar 24, the value is 0.01. This value is below the healthy minimum of 5. There is no change compared to the previous period (Mar 23) which recorded 0.01.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
Unable to fetch valid data for stock valuation.Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Aashka Hospitals Ltd:
- Net Profit Margin: 14.42%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 4.39% (Industry Average ROCE: 15.48%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 3.28% (Industry Average ROE: 14.81%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 2.36
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 1.25
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 185 (Industry average Stock P/E: 101.54)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.12
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 14.42%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Hospitals & Medical Services | Between Sargasan & Reliance Cross Road, Sargasan, Gandhinagar Gujarat 382421 | cs@aashkahospitals.in http://www.aashkahospitals.in |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Bipinchandra D Shah | Chairman & Managing Director |
| Mrs. Shreyarthi B Shah | Director |
| Mr. Umang A Shah | Independent Director |
| Mr. Jigar K Trivedi | Independent Director |